Synergic Effect of Cisplatin, Adriamycin, and Cyclophosphamide Combination Chemotherapy and Radiotherapy in Non-Small Cell Lung Cancer
- 1 January 1985
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 42 (1) , 1-6
- https://doi.org/10.1159/000225991
Abstract
61 patients with inoperable non-small cell lung cancer were treated by combination chemotherapy with cisplatin, Adriamycin and cyclophosphamide. 23 patients received radiotherapy in addition to the chemotherapy. 49 out of 55 adequately treated patients were evaluable for tumor response. Of 29 patients who received chemotherapy alone, 6 (21%) achieved partial responses. Of 20 patients who received combined chemotherapy and radiotherapy, 16 (80%) achieved complete or partial responses. The median survival time was 18 months for 22 patients treated with combined therapies.Keywords
This publication has 3 references indexed in Scilit:
- Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancerCancer, 1983
- Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: A prospective studyInternational Journal of Radiation Oncology*Biology*Physics, 1982
- SIMULTANEOUS TREATMENT WITH CISPLATIN AND RADIATION-THERAPY FOR ADVANCED SOLID TUMORS - A PILOT-STUDY1981